Sickle Cell Anemia Therapeutics Market Analysis, Challenges, Top Manufacturers, Key Countries With Forecast To 2027
Sickle Cell Anemia Therapeutics Market report provides key enumeration on the Market status of the Sickle Cell Anemia Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using an objective combination of primary and secondary information including inputs from key participants in the Sickle Cell Anemia Therapeutics industry. It delivers important information to identify and analyse the market need, market Growth and competition.
The global Sickle Cell Anemia Therapeutics Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Sickle Cell Anemia Therapeutics Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Sickle cell anemia therapeutics include medication, blood transfusions, and sometimes a bone-marrow transplant. Sickle-cell diseases are types of blood disorders which are usually inherited genetically. Currently, hematopoietic stem cell transplant is the only curative therapy available for patients with sickle cell disease. However, hematopoietic stem cell transplant is a rigorous, time-consuming, potentially high-risk procedure; it is only used when the benefits of a cure outweigh the considerable risks of the procedure, and only when a suitable donor is available. One of the common types of sickle cell diseases is the sickle cell anemia.
Therefore, growth of the sickle cell anemia therapeutics market is attributed to the increasing prevalence of sickle cell anemia, especially in the United States. Sickle cell disease is among the most common genetic diseases in the U.S. According to the Centers for Disease Control and Prevention (CDC), sickle cell disease affects around 70,000 to 100,000 people in the U.S. However, the exact number of people living with sickle cell disease in the U.S. is unknown. Thus, with the increasing prevalence of sickle cell anemia, the demand for sickle cell anemia therapeutics is also increasing in this region.
For example, in November 2019, the Food and Drug Administration (FDA) granted accelerated approval to voxelotor (Oxbryta, Global Blood Therapeutics) for adults and pediatric patients 12 years of age and older with sickle cell disease. Moreover, November 2019, FDA approved crizanlizumab-tmca (ADAKVEO, Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. This in turn is expected to augment the growth of the sickle cell anemia therapeutics market in North America, especially in the U.S.
Sickle cell disease is common among people of Middle Eastern, African, and South Asian descent. Sickle cell anemia can have genotypic and phenotypic variants based on different mutations in hemoglobin genes. Sickle cell diseases, such as sickle cell anemia, are very common among Black or African Americans. According to the CDC, sickle cell disease occurs among about 1 out of every 365 Black or African-American births. Moreover, around 1 in 13 Black or African-American babies born with sickle cell trait. The increasing prevalence of the disease will increase the demand for prevention and treatment of sickle cell disease.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/161
Sickle Cell Anemia Therapeutics Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Bristol-Myers Squibb, GlycoMimetics, Pfizer,Anthera Pharmaceuticals Inc., GlycoMimetics, Inc., Eli Lilly, and Mast Therapeutics
Main points in Sickle Cell Anemia Therapeutics Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Sickle Cell Anemia Therapeutics Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Sickle Cell Anemia Therapeutics Industry Impact
Chapter 2 Global Sickle Cell Anemia Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Sickle Cell Anemia Therapeutics (Volume and Value) by Type
2.3 Global Sickle Cell Anemia Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Sickle Cell Anemia Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Sickle Cell Anemia Therapeutics Market Analysis
Chapter 6 East Asia Sickle Cell Anemia Therapeutics Market Analysis
Chapter 7 Europe Sickle Cell Anemia Therapeutics Market Analysis
Chapter 8 South Asia Sickle Cell Anemia Therapeutics Market Analysis
Chapter 9 Southeast Asia Sickle Cell Anemia Therapeutics Market Analysis
Chapter 10 Middle East Sickle Cell Anemia Therapeutics Market Analysis
Chapter 11 Africa Sickle Cell Anemia Therapeutics Market Analysis
Chapter 12 Oceania Sickle Cell Anemia Therapeutics Market Analysis
Chapter 13 South America Sickle Cell Anemia Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Sickle Cell Anemia Therapeutics Business
Chapter 15 Global Sickle Cell Anemia Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
- CDN Newswire